The Dermatology Digest

APRIL 11, 2025

SciBase is launching the next generation of Nevisense, Nevisense V. Nevisense by SciBase utilizes electrical impedance spectroscopy to measure how electricity flows through skin at different depths for the non-visual detection of malignant melanoma. The new platform features an updated user interface, enhanced display resolution, and an upgraded, more user-friendly touchscreen.

Technology 56

Technology Marketing Clinic Dermatology 56

Dermatology Times

APRIL 11, 2025

Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumabs 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumabs 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.

Safety 36

Safety Sustainability 36

The Dermatology Digest

APRIL 11, 2025

Palvella Therapeutics, Inc. s QTORIN rapamycin 3.9% anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. There are no U.S. Food and Drug Administration (FDA)-approved therapies for microcystic LMs.

Therapy 36

Therapy Dermatology Office Clinic 36

Dermatology Times

APRIL 11, 2025

Satisfaction levels remained high at 12 weeks post-treatment among those who received acupuncture.

Clinic 64

Clinic Treatments 64

The Dermatology Digest

APRIL 11, 2025

Sun Pharma is no longer under any court order that delays or restricts the launch of deuruxolitinib (Leqselvi) after receiving a favorable ruling from a New Jersey federal court, according to media reports. The U.S. Food and Drug Administration (FDA) approved deuruxolitinib (Leqselvi, Sun Pharma) for adults with severe alopecia areata in 2024. This is the third Janus kinase (JAK) inhibitor approved for alopecia.

Medical 36

Medical Dermatology 36

Beauty Launchpad

APRIL 11, 2025

As the largest beauty event of the year, Premiere Orlando is where the industry's best and brightest come to learn, grow and connect.

59

59

Beauty Launchpad

APRIL 11, 2025

After weeks of deliberation and three rounds of judging Denmans inaugural College Star USA has announced its winners.

52

52

Advanced Dermatology

APRIL 11, 2025

Want to know how to look younger and combat concerns like hollow cheeks? Read about dermal fillers and how they provide countless anti-aging benefits.

36

36

Dermatology Times

APRIL 11, 2025

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Dermatology 36

Dermatology 36

Beautiful With Brains - Skincare

APRIL 11, 2025

Do exfoliating cleansers work? Mmm… You need cleanse and exfoliate. These steps AREN’T optional. Why not buy an exfoliating cleanser and do both at the same time? It’ll save you money and time in the evening, right? Not so fast… There are two types of cleansing exfoliants: physical and chemical. One of them doesn’t work. […] The post Do Exfoliating Cleansers Work?

Exfoliation 84

Exfoliation Skincare 84

Dermatology Times

APRIL 11, 2025

While approved for vitiligo and atopic dermatitis, ruxolitinib cream may help treat other inflammatory skin diseases.

Dermatitis 36

Dermatitis 36

Dermatology Times

APRIL 11, 2025

The presentation, led by Amy Paller, MS, MD, highlighted the upcoming phase 3 SELVA study for microcystic lymphatic malformations.

Dermatology 36

Dermatology 36

Dermatology Times

APRIL 11, 2025

Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.

Treatments 36

Treatments 36

Dermatology Times

APRIL 11, 2025

An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patients GEP risk level would influence the approach to surveillance and follow-up.

Treatments 36

Treatments 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how pediatric atopic dermatitis (AD) burdens entire families through sleep disruption and emotional toll. Parents seek effective nonsteroidal options beyond current treatments. Convenient topical Janus kinase (JAK) inhibitors could improve adherence and outcomes.

Dermatitis 36

Dermatitis Therapy Treatments 36

Dermatology Times

APRIL 11, 2025

Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.

Safety 36

Safety 36

Dermatology Times

APRIL 11, 2025

Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.

Dermatitis 36

Dermatitis Treatments 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.

Treatments 36

Treatments Dermatitis 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.

Dermatitis 36

Dermatitis Sustainability Management Treatments 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 211, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.

Dermatitis 36

Dermatitis Management Treatments 36

Dermatology Times

APRIL 11, 2025

Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.

Treatments 36

Treatments 36

Dermatology Times

APRIL 11, 2025

Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.

Therapy 36

Therapy Safety Medical Treatments 36

Dermatology Times

APRIL 11, 2025

Menopausal acne is rising yet underexplored; treatment must address hormonal shifts, skin sensitivity, and patient emotional well-being.

Skin Sensitivity 36

Skin Sensitivity Treatments 36

Dermatology Times

APRIL 11, 2025

The company also announced in a press release that the product received the Seal of Acceptance by the NEA.

Eczema 36

Eczema 36